Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 30, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 2, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references dividend reinvestment
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001171780-26-000014
Filed / recorded
Oct 2, 2026, 9:00 PM UTC
Added to OQRO
Oct 2, 2026, 10:30 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
AbbVie Inc.
Issuer CIK
1551152
Ticker
ABBV
Reporting person
Edward J Rapp
Relationship
Director
Security
Stock Equivalent Units
Table
Derivative (Table II)
Transaction date
Sep 30, 2026
Transaction code
A
Shares / units
129
Price per share
$261.59
Acquired / disposed
Acquired (A)
Shares owned after
29,568
Ownership form
Direct
Amendment
No
Footnotes from the filing
Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.